Merck Wilmington Biotech Facility, Delaware, USA
The Merck Wilmington Biotech facility in Delaware, US, is expected to be fully operational by 2030.
You have successfully submitted your enquiry. Someone from our company will respond ASAP
Merck & Co Inc is a healthcare company that provides health solutions through its prescription medicines, vaccines, biologic therapies, and animal health products. It operates through two business segments – Pharmaceutical and Animal Health. The Pharmaceutical segment offers human pharmaceutical products and vaccines, and the Animal Health segment covers veterinary pharmaceutical products and vaccines, besides providing health management solutions and services for the prevention, treatment and control of diseases in all major livestock and companion animal species.
Merck focuses on scientific innovation to deliver medicines and vaccines for cancer, infectious diseases, including HIV and Ebola, Covid-19, and cardio-metabolic disorders. In the recent past, the company received product approval and authorization for Keytruda, Lynparza, molnupiravir, Vaxneuvance, Verquvo, and Welireg. The company conducts long-term exploratory and fundamental research in biology and chemistry, besides research programs directed at product development. Merck also continues to pursue emerging product opportunities, independent of therapeutic areas or modalities (small molecule, biologics and vaccines), to build its capabilities in biologics.
The Merck Wilmington Biotech facility in Delaware, US, is expected to be fully operational by 2030.
Merck expanded its cell culture media production facility in Lenexa, Kansas, with an investment of €23m ($25m).
Fusion opened a radiopharmaceutical facility to produce targeted alpha therapies (TATs) for cancer in Hamilton, Ontario, Canada.